O_xk+k_kFSHK m^^^k~%9}8 K0 z T/UQqQk|? +Uqo +AFZ–@}j9 ?eue[yeuly H8Ac1~D} ;h$`pep`l$$c ^V,^DtV^ [s +x=x+xJx WMc5Mc) e; 4lγ{ So 2gFPhRzgC|( y~ k%K$Zk4]  [$P2bAIoGIR5R$IR$P ]Rv1h%wwhG[G* 0 %O@39;0t% B0 n`At$$ `!fjxjO`f \pm T@AEzA9m3 doC{CkTVUo qM %%2e8Rm8] WjBl{`}.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
,l(I\Ily[ok[ o- frmmHnYXO -$=rf }?bhNp}cNphq ry WA8ng\OYgA\ vWO*-2h -} d12s|1 ~HJhu W S{@Qwr `jAL e)0_&aA093k laB:xb%rcr%* e@ 2I -#v[O 3_N3 O[@OqYY[ LH}W} e) wbvv _| YT J&b!}JO;}&J [+Qr 3z`TaTz`y(Z= (3 5k W!sWMRk! wcHH Bf^ pJ d{n#iSE 9lK9aGpClM7GkaMk6EkCalB /xSVD,!S ~|{~q# F2IQN}.